Figure 4: Targeting GRAMD1B for OvCa treatment. | Nature Communications

Figure 4: Targeting GRAMD1B for OvCa treatment.

From: 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

Figure 4

(a) A Venn diagram for identification of novel targets for the treatment of OvCa. (b) Expression of GRAMD1B, RBBP6 and SLC23A1, in a panel of chemosensitive and chemoresistant OvCa cell lines. (c) Protein expression of GRAMD1B in taxane-sensitive (HeyA8 and SKOV3ip1) and taxane-resistant (HeyA8-MDR and SKOV3-TR) OvCa cells (n=1). Effect of GRAMD1B downregulation on (d) cell viablity and (e) apoptosis in HeyA8-MDR cells. (f) Effect of knockdown of GRAMD1B on the sensitivity of HeyA8-MDR cells to paclitaxel or docetaxel treatment. Cell viability is expressed as a percentage of that measured in siRNA monotherapy-treated wells. (g) Effect of GRAMD1B protein expression on overall survival in OvCa patients (n=156). Scale bar, 100 μm. (P-values obtained with (a–f) Student’s t-test or (g) log-rank test; (b) ***P<0.001 or ****P<0.0001; compared with the corresponding chemosensitive cell line; (d–f) *P<0.05 or **P<0.01; compared with cells treated with siCon; bars and error bars represent mean values and the corresponding s.e.m.s (n=3).)

Back to article page